



SA Health Cancer Drug Committee

July 2017





Αŗ

Applicar	t Details	
Consu	Itant Name:	
	Il Unit, Hospital/LHN:	
Teleph Mobile	none:	Pager: Email:
IVIODITE	<u>. </u>	Lilidii.
Supporti	ng Tumour Stream Lead Detail	ls
Consu	Itant Name: on:	
	ll Unit, Hospital/LHN:	
Teleph		Pager:
Mobile	:	Email:
Supporti	ng Specialist Pharmacist Deta	ils
Name Position		
Clinica	ll Unit, Hospital/LHN:	
Teleph		Pager:
Mobile	:	Email:
Supporti	ng Specialist Nurse Details	
Name		
Position	n: ıl Unit, Hospital/LHN:	
Teleph		Pager:
Mobile		Email:
SA Healt	h Cancer Drug Committee Use	only:
Applic	ation received (date):	
Confir	mation of costing confirmed*	
Appro	val Status	
APPR	OVED 🗆	
Condi	ions of approval (if any):	
REJE	CTED 🗆	
Reaso	n(s) for rejection:	
Treatn	nent Risk Level allocated:	
SAH-0	CDC comments (if any)	
and co		of my knowledge the information contained within is correct lth Cancer drug Committee in submitting this protocol to the SA col Register:
SAH-0	CDC Chair (or delegate):	Position:
Signat	ure:	Date:

Protocol Name	
Protocol Number	

2

Protocol Title (INDICATION, Regimen Name) -

reatment S	Treatment Schedule - Summary				
Drug	Dose	Route	Day		
Frequency:					
		1 11 11 N			
Notes (e.g. 1	line treatment, alternate sche	eduling options):			
Number of Cy	/cles:				
Protocol					
Protocol					
Indications ar	nd Patient Population:				
Indications fo					
indications id	or use:				
Exclusions (e	.g. low GFR):				
Notes:					
_					
Drug Status	s (PBS status, formul	lation etc.):			

Venous access requirements		
Supportive Care/		
Premedication		
Hypersensitivity/infusion		
related reaction		
Emetogenicity		
Drug reactions		
Blood tests		
Hepatitis B screening and		
prophylaxis		
Vaccinations		
Effects of cancer treatment on fertility		
Other:		
Treatment Schedule - I	Detailed	
Drug	Dose	Administration/frequency
Diag		Administration/frequency
Frequency:		
Number of Cycles:		
Dose Modifications:		
Haematological Toxicity		
ANC		
Platelets		
- Ideoloto		
Haemoglobin		

Clinical Information:

Creatinine clearance (mL/min):				
Hepatic Impairment				
Mucositis and stomatitis				
Neurotevielty				
Neurotoxicity				
Other Toxicities				
Interactions:				
Drug	Interaction	Clinical management		
Diag	Interdetion	Omnour management		
General Interactions				
	Interaction	Clinical management		
A desiminate of the details				
Administration details				
General patient assessment:				
Pre-treatment medications:				
Chemotherapy - ③ Time out checklist				
Discharge_Information				
Monitoring				
Tests/assessments Frequency				

Blood tests			
Side-effects			
Immediate (onset ho	urs to days)		
Early (onset days to	weeks)		
Late (onset weeks to	months)		
Supporting Docui	ments		

For more information

Medicines and Technology Programs (MTP) and Out of Hospital Pharmacy Services
Department for Health and Ageing
Level 8, Citi Centre
11 Hindmarsh Square
Adelaide, SA 5000
Telephone: +61 8 8226 7080

www.sahealth.sa.gov.au





